Files and links (2)
Published VersionCC BY-NC-ND V4.0, Open Access
Journal article
Experimental study of 131 I-caerin 1.1 and 131 I-c(RGD) 2 for internal radiation therapy of esophageal cancer xenografts
Biomedicine & Pharmacotherapy, Vol.164, pp.1-10
2023
PMID: 37209630
Abstract
Objective:
The aim of this study was to analyze and compare the therapeutic effects of 131I-caerin 1.1 and 131I-c(RGD)2 on TE-1 esophageal cancer cell xenografts.
Methods:
(1) The in vitro antitumor effects of the polypeptides caerin 1.1 and c(RGD)2 were verified by MTT and clonogenic assays. 131I-caerin 1.1 and 131I-c(RGD)2 were prepared by chloramine-T (Ch-T) direct labeling, and their basic properties were measured. The binding and elution of 131I-caerin 1.1, 131I-c(RGD)2, and Na131I (control group) in esophageal cancer TE-1 cells were studied through cell binding and elution assays. (2) The antiproliferative effect and cytotoxicity of 131I-caerin 1.1, 131I-c(RGD)2, Na131I, caerin 1.1 and c(RGD)2 on TE-1 cells were detected by Cell Counting Kit-8 (CCK-8) assay. (3) A nude mouse esophageal cancer (TE-1) xenograft model was established to study and compare the efficacy of 131I-caerin 1.1 and 131I-c(RGD)2 in internal radiation therapy for esophageal cancer.
Results:
(1) Caerin 1.1 inhibited the in vitro proliferation of TE-1 cells in a concentration-dependent manner, with an IC50 of 13.00 µg/mL. The polypeptide c(RGD)2 had no evident inhibitory effect on the in vitro proliferation of TE-1 cells. Therefore, the antiproliferative effects of caerin 1.1 and c(RGD)2 on esophageal cancer cells were significantly different (P < 0.05). The clonogenic assay showed that the clonal proliferation of TE-1 cells decreased as the concentration of caerin 1.1 increased. Compared with the control group (drug concentration of 0 µg/mL), the caerin 1.1 group showed significantly lower clonal proliferation of TE-1 cells (P < 0.05). (2) The CCK-8 assay showed that 131I-caerin 1.1 inhibited the in vitro proliferation of TE-1 cells, while 131I-c(RGD)2 had no evident inhibitory effect on proliferation. The two polypeptides showed significantly different antiproliferative effects on esophageal cancer cells at higher concentrations (P < 0.05). Cell binding and elution assays showed that 131I-caerin 1.1 stably bound to TE-1 cells. The cell binding rate of 131I-caerin 1.1 was 15.8 % ± 1.09 % at 24 h and 6.95 % ± 0.22 % after 24 h of incubation and elution. The cell binding rate of 131I-c(RGD)2 was 0.06 % ± 0.02 % at 24 h and 0.23 % ± 0.11 % after 24 h of incubation and elution. (3) In the in vivo experiment, 3 days after the last treatment, the tumor sizes of the phosphate-buffered saline (PBS) group, caerin 1.1 group, c(RGD)2 group, 131I group, 131I-caerin 1.1 group, and 131I-c(RGD)2 group were 68.29 ± 2.67 mm3, 61.78 ± 3.58 mm3, 56.67 ± 5.65 mm3, 58.88 ± 1.71 mm3, 14.40 ± 1.38 mm3, and 60.14 ± 0.47 mm3, respectively. Compared with the other treatment groups, the 131I-caerin 1.1 group had significantly smaller tumor sizes (P < 0.001). After treatment, the tumors were isolated and weighed. The tumor weights in the PBS group, caerin 1.1 group, c(RGD)2 group, 131I group, 131I-caerin 1.1 group, and 131I-c(RGD)2 group were 39.50 ± 9.54 mg, 38.25 ± 5.38 mg, 38.35 ± 9.53 mg, 28.25 ± 8.50 mg, 9.50 ± 4.43 mg, and 34.75 ± 8.06 mg, respectively. The tumor weights in the 131I-caerin 1.1 group were significantly lighter than those in the other groups (P < 0.01).
Conclusion:
131I-caerin 1.1 has tumor-targeting properties, is capable of targeted binding to TE-1 esophageal cancer cells, can be stably retained in tumor cells, and has an evident cytotoxic killing effect, while 131I-c(RGD)2 has no evident cytotoxic effect. 131I-caerin 1.1 better suppressed tumor cell proliferation and tumor growth than pure caerin 1.1, 131I-c(RGD)2, and pure c(RGD)2.
Details
- Title
- Experimental study of 131 I-caerin 1.1 and 131 I-c(RGD) 2 for internal radiation therapy of esophageal cancer xenografts
- Authors
- Tiantian He (Author) - Guangdong Pharmaceutical UniversityJuan Du (Author) - Guangdong Pharmaceutical UniversityKeke Zhu (Author) - Guangdong Pharmaceutical UniversityYixuan Zhou (Author) - Guangdong Pharmaceutical UniversityZewei Xiao (Author) - Guangdong Pharmaceutical UniversityWenjie Liu (Author) - Guangdong Pharmaceutical UniversityWeiwei Ren (Author) - Guangdong Pharmaceutical UniversityXiongying Liu (Author) - Guangdong Pharmaceutical UniversityTongsheng Chen (Author) - Guangdong Pharmaceutical UniversityWenjuan Liu (Author) - Guangdong Pharmaceutical UniversityZhuanming Chen (Author) - Guangdong Pharmaceutical UniversityGuoying Ni (Author) - Guangdong Pharmaceutical UniversityXiaosong Liu (Author) - Guangdong Pharmaceutical UniversityTianfang Wang (Author) - University of the Sunshine Coast, Queensland, School of Science, Technology and EngineeringJiangtao Quan (Corresponding Author) - General Hospital of the Southern Theatre Command (China)Peipei Zhang (Corresponding Author) - First People's Hospital of FoshanJianwei Yuan (Corresponding Author) - Guangdong Pharmaceutical University
- Publication details
- Biomedicine & Pharmacotherapy, Vol.164, pp.1-10
- Publisher
- Elsevier Masson
- Date published
- 2023
- DOI
- 10.1016/j.biopha.2023.114891
- ISSN
- 1950-6007; 0753-3322
- PMID
- 37209630
- Copyright note
- © 2023 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
- Organisation Unit
- School of Science and Engineering - Legacy; GeneCology Research Centre - Legacy; School of Science, Technology and Engineering; Centre for Bioinnovation
- Language
- English
- Record Identifier
- 99727996202621
- Output Type
- Journal article
Metrics
17 File views/ downloads
39 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- International collaboration
- Web Of Science research areas
- Medicine, Research & Experimental
- Pharmacology & Pharmacy
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites